Docket Number:12A-1050118
Inventor:Eminy H.Y. Lee, Derek Jui-Cheng Tai, Yen-Chen Liu, Wei-Lun Hsu
IP Status:TW I601821, Pending
Abstract:
Rett Syndrome (RTT) is caused by mutations of the MeCP2 gene and RTT patients have severe neural and behavioral deficits. We first demonstrate that various MeCP2 mutations associated with RTT all show significant decrease in MeCP2 SUMOylation. By using a mouse model of RTT, we show that increase in MeCP2 SUMOylation rescues the neural and behavioral deficits in these animals.
Fields of Application:
We found that MeCP2 SUMOylation is significantly decreased in Mecp2 conditional knockout mice and transduction of MeCP2-SUMO1 fusion vector rescues the neural and behavioral deficits of these animals. Based on these findings, the possible application scopes are: (1) to develop the specific antibody against Lys-412 of MeCP2 so that we can screen potential therapeutic drugs against RTT based on their influence on MeCP2 SUMOylation at Lys-412, (2) to assess the effect of currently adopted drugs for alleviation of RTT on MeCP2 SUMOylation and the degree of increase in MeCP2 SUMOylation may be used as a criterion of their clinical efficacy.
Advantages when compared to the existing technologies:
The advantage of the present findings are identification of a novel molecular mechanism underlying RTT and offering of an index for screening potential therapeutic drugs against RTT based on their effect on MeCP2 SUMOylation. Currently, there are a few drugs used for alleviating RTT, but they can not pass the blood-brain-barrier (BBB). We provide a tool for screening new drugs that can pass the BBB for further evaluation of their effect on MeCP2 SUMOylation. Drugs that reach both criteria could be tested in Mecp2 mutant mice first. If the effect is positive, they could be further considered having potential in treating RTT patients.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
